AAV-mediated silencing of Sox4 leads to long-term amelioration of liver phenotypes in mouse models of Alagille syndrome

BACKGROUND & AIMS

In patients with Alagille syndrome (ALGS), bile duct paucity often leads to severe cholestatic phenotypes for which liver transplantation remains the only definitive treatment. No FDA-approved mechanism-based strategies exist to enhance biliary development in ALGS or other diseases with bile duct paucity. We aimed to identify a therapeutic target to address this unmet need.

METHODS

Preclinical ALGS mouse models lacking one copy of Jag1 with or without conditional deletion of one or both copies of Sox9 were used. Sox4 levels were reduced genetically or with adeno-associated virus 8 (AAV8) vectors driving a Sox4-silencing sequence. Liver histology, biliary tree ink injection, serum chemistry, RNAscope (on mouse and human livers), mouse liver single-cell RNA-sequencing (scRNA-Seq), and reanalysis of published human liver bulk RNA-Seq were performed.

RESULTS

Conditional removal of one copy of Sox4 in mouse liver significantly improved the ALGS liver phenotypes in a Sox9-dependent manner. An increase in Sox4/SOX4 expression in early postnatal Jag1-heterozygous mouse livers and ALGS patient livers was observed. scRNA-Seq revealed the appearance of an intermediate hepatobiliary cluster co-expressing Sox4 and Sox9 in Jag1-heterozygous livers. AAV8-mediated Sox4 knockdown, ubiquitously or driven by the hepatocyte-specific TBG promoter, led to long-term improvement of ALGS liver phenotypes upon injection at postnatal day 1 (P1). AAV8 injection at P15—after the appearance of liver necrosis—led to the incorporation of some transduced cells into bile ducts and phenotypic improvement.

CONCLUSIONS

Preclinical studies provide proof of principle for postnatal AAV-mediated Sox4 knockdown in TBG⁺ cells as a therapeutic approach for ALGS liver disease.